| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8233007 | International Journal of Radiation Oncology*Biology*Physics | 2010 | 7 Pages |
Abstract
In this feasibility study, weekly administration of cisplatin and cetuximab was safely combined with accelerated RT, supported with amifostine, at the cost of a high incidence of acneiform rash but a reduced incidence of amifostine-related fever/rash. A high daily dose of amifostine allows completion of therapy with minor delays.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Michael I. M.D., Pelagia G. M.D., Antonios M.D., Maria M.Sc., Ilias M.D., Vassilios M.D., Constantinos Kouskoukis,